LAUSANNE, Switzerland, Nov. 10, 2016 /PRNewswire/ -- Today, at the AMP 2016 Annual Meeting, Sophia Genetics, global leader in Data-Driven Medicine, and world-class Next-Generation Sequencing (NGS) assay developer ArcherDX, announced the signing of a new partnership to combine their technological solutions. The partnership will focus on oncology solutions addressing solid tumours and haematological disorders, as well as applications in liquid biopsy and immune repertoire profiling.
The agreement sees Sophia Genetics integrate the ArcherDX portfolio of NGS test kits into the Sophia DDM ® analytical platform and offer the combined solutions to its ever-expanding network of hospitals and laboratories around the world. This partnership provides Sophia DDM ® users with the unique experience of SOPHiA™ artificial intelligence making the most out of research samples prepared with ArcherDX sample preparation assays. Research hospitals and laboratories will benefit not only from comprehensively detecting all kinds of genomic alterations in a single test, such as SNVs, INDELs, CNVs and gene fusions, but also from faster adoption of the solutions in clinical research and superior analytical performance. As more research laboratories use Sophia DDM® and upload sample genomic data, SOPHiA™ will continuously learn, providing ever more accurate and personalised characterizations of genomic alterations and treatments. Jason Myers, Ph.D., CEO at ArcherDX, said, "This exciting partnership with Sophia Genetics will help to decentralize NGS-based testing in molecular laboratories. By joining forces, ArcherDX and Sophia Genetics are enabling international laboratories of all sizes using SOPHiA™ to access and report on cutting-edge applications that ArcherDX has developed, including gene fusions, liquid biopsies, and immune repertoire profiling." Through Sophia DDM ®, a clinical genomics community of more than 215 laboratories and hospitals in over 35 countries will have the opportunity to use Sophia Genetics and ArcherDX combined solutions to precisely identify disease-associated mutations with advanced genomic tests. Jurgi Camblong, CEO and co-founder of Sophia Genetics commented, "This new partnership allows us to continue building the ecosystem around Sophia DDM ®. We're committed to continuing to help unlock the power of data analysis for our fast-growing clinical genomics community. ArcherDX's purpose-built technologies for targeted NGS solutions will help SOPHiA™ generate precision results accessible on Sophia DDM ®, thus further democratizing Data-Driven Medicine." Sophia Genetics' and ArcherDX's partnership launches worldwide immediately, helping laboratories transition to NGS, obtain improved throughput, reduce hands-on time and generate reliable results.